Feature | ASTRO | October 30, 2018

Late-breaking Radiation Therapy Clinical Trials at ASTRO 2018

ASTRO 2018 Radiation Therapy Clinical Trials. #ASTRO2018 #ASTRO18 #ASTRO

October 30, 2018 — The American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting included 10 top-rated clinical studies. The ASTRO 2018 annual meeting, held Oct. 21-23 in San Antonio, Texas drews more than 11,000 attendees.

The highlighted studies below are linked to full articles. 

 

Advances in Breast and Lung Cancers

Sunday, Oct. 21

 

Advances in Genitourinary Cancers

Monday, Oct. 22

 

Advances in Oral and Oligometastatic Cancers

Tuesday, Oct. 23

 

Other ASTRO News and Videos:

Trends in Proton Therapy at ASTRO 2018 — Faster Therapy Delivery, Single-room Installs

 

SBRT Considered Safe Treatment Option for Patients With Multiple Metastases

VIDEO: Radiation Oncology Reimbursement Update From ASTRO — Interview with Anne Hubbard, MBA, ASTRO director of health policy

Hippocampal Sparing Prevents Whole-Brain Radiotherapy Cognitive Side Effects

VIDEO: Biologically Guided Radiation Therapy Using Real-time PET Imaging — Interview with Kristin Higgens, M.D., Emory 

Smart Machines To Empower Oncology Docs and Patients, Say ASTRO Experts

VIDEO: Beaumont's Experience With Proton Therapy After One Year — Interview with Peyman Kabolizadeh, M.D., Beaumont Proton Therapy Center

Biology Guided Radiotherapy May Improve Physician Confidence in Treatment of Multiple Tumors

VIDEO: The Use of Nanoparticles in Radiation Therapy — Interview with James Welsh, M.D., MD Anderson Cancer Center

Market for MRI-based RT Could Soon Widen

VIDEO: FDA-cleared Bra Helps Improve Breast Positioning During Radiation Therapy — Interview with Elizabeth Chabner-Thompson, M.D., MPH

Prostate Brachytherapy Shows Low Incidence of Short-Term Complications

VIDEO: Use of Liquid Biopsies to Assess Radiotherapy Response — Interview with Aadel Chaudhuri, M.D.

360 View of the Dedicated Radiotherapy Magnetom Sola 1.5T MRI System

VIDEO: Personalizing Radiotherapy Using Genomic Markers of Radiosensitivity — Interview with Javier Torres-Roca, M.D.

VIDEO: Improving Breast Cancer Surgery With Electronic Brachytherapy IORT —  Interview with A. M. Niser Syed, M.D.

360 View of a GE Healthcare Discovery RF Gen 2 Dedicated Radiation Therapy CT System
 

 

 

For more information: www.astro.org

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 New studies use SIRD model to forecast COVID-19 spread; examine patient CT scans to correlate clinical features with mortality

Fig 1. A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63. It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)) Yuan et al, 2020 (CC BY 4.0)

News | Coronavirus (COVID-19) | April 01, 2020
April 1, 2020 — A new study, ...
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...